A Phase III clinical trial is now underway in the pivotal study of interferon alfa-2b gene therapy in pleural mesothelioma. After promising results from the Phase II clinical trial, scientists and researchers are hopeful they are just one step away from FDA approval for this cancer treatment that is over[…]
Novel Treatments & Drugs
Targeted Immunotherapy Warrants More Research for Those Suffering from Pleural Mesothelioma
Late last month, the Clinical Respiratory Journal released their findings on the efficacy of intrapleural immunotherapy, which is a highly targeted approach of receiving immunotherapy treatment for those suffering from mesothelioma. Mesothelioma is a cancer caused only by asbestos exposure. Since asbestos is the only known cause, mesothelioma is sometimes[…]
FDA Approves Genetic-Based Cancer Treatment that Could Help Mesothelioma Patients
Correcting genes that allow cancerous tumors to grow is the basis behind gene therapy, a relatively new treatment that is largely in experimental stages. The initial goals of gene therapy were to address hereditary genetic disorders, but other factors such as the sun, smoking, chemical exposure, etc., can all damage[…]
Acupuncture as Potential Palliative Care for Mesothelioma Patients
When one thinks of acupuncture, one may envision a nice relaxing trip to a day spa, where after a long massage or a relaxing facial, tension in body can be further relieved through this ancient practice where thin needles are inserted into the body. However, this traditional Chinese medicine may[…]
Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results
Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]
Survival Improves in Mesothelioma Patients who Received an Electricity-Based Treatment
The success of a recent Phase II clinical trial in malignant pleural mesothelioma has scientists and researchers excited about the possibility of adding a new treatment that will not only improve survival, but also improve quality of life of the cancer patient. Tumor Treating Fields, which is a therapy that[…]
New Surgical Technique Illuminates Previously Undetected Mesothelioma Tumors
In addition to chemotherapy, radiation therapy, and immunotherapy, those suffering from mesothelioma also have the option for surgery (if they are physically able). Surgery is one of the better options for mesothelioma patients because it can remove most if not all the cancer; however, often times since the cancer is[…]
Potential Breakthrough in Immunotherapy after Nivolumab Study Results
Immunotherapy treatments have once again made headlines, revolutionizing modern medicine and the way we have come to understand cancer treatment. The latest study results published in the American Journal of Case Reports, focuses on Opdivo (nivolumab), a type of check point inhibitor designed to stop immune cells from attacking the[…]
Nintedanib May Surpass Bevacizumab as a More Effective Chemotherapy Treatment for Mesothelioma
In 2016, scientists and researchers were excited to begin Phase II of the clinical trial involving treating patients with malignant pleural mesothelioma with Nintedanib, a triple angiokinase inhibitor designed to hinder protein kinases in cancer cells and stop cancer cells from growing their own blood vessels. The LUME-Meso Phase II[…]
Immunotherapy – What Side Effects Can You Expect?
As the success of immunotherapy treatments in improving survival and symptom management for cancer patients have started to become known, those suffering from cancer such as mesothelioma and lung cancer may now be given options in terms of the best course of treatment. Immunotherapy works with the body’s own natural[…]
